0001104659-24-031806.txt : 20240307 0001104659-24-031806.hdr.sgml : 20240307 20240307132720 ACCESSION NUMBER: 0001104659-24-031806 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240305 FILED AS OF DATE: 20240307 DATE AS OF CHANGE: 20240307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sabba Stephen L CENTRAL INDEX KEY: 0001442372 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 24729315 MAIL ADDRESS: STREET 1: DORSET MANAGEMENT CORP STREET 2: 485 UNDERHILL BLVD SUITE 205 CITY: SYOSSET STATE: NY ZIP: 11791 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 tm248239-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-03-05 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001442372 Sabba Stephen L DORSET MANAGEMENT CORP 485 UNDERHILL BLVD SUITE 205 SYOSSET NY 11791 1 0 0 0 0 Common Stock 2024-03-05 4 M 0 2893 0.00 A 30819 D Common Stock 2024-03-05 4 S 0 1893 74.30 D 28926 D Non-Qualified Stock Option (right to buy) 67.53 2024-03-05 4 M 0 2893 0 D 2024-06-04 Common Stock 2893 419 D These securities, as represented in Column 5, include a grant of 1,142 restricted share units approved by the Board of Directors of the Company at the 2023 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. They also properly reflect adjustments from the OmniAb Inc. separation from the Issuer. The Shares referenced in Column 5 of Table I as disposed of on the Form 4 filed 5/10/23 for this Reporting Person inadvertently failed correctly to reflect those adjustments. That number should have been 26,784. These securities, as represented in Column 5, were acquired by a grant of 3,312 shares by the Board of Directors of the Company at the 2014 Meeting. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. This Option was previously reported on the Form 4 filed 6/6/14 as a Grant of 3,312 shares, which vested in full on April 24, 2015, at an exercise price of $67.53 per share, but was adjusted pursuant to the OmniAb Inc. separation from the Issuer. By: /s/ Stephen L. Sabba 2024-03-07